📊 NVACW Key Takeaways
Is Profusa, Inc. (NVACW) a Good Investment?
Profusa is a pre-revenue or near-zero revenue medical device company with severe financial distress characterized by massive operating losses (-$24.1M), negative stockholders' equity (-$34.0M), and critical cash burn (-$11.1M operating cash flow). The company's liabilities ($38.2M) far exceed assets ($4.2M), and liquidity metrics indicate imminent solvency concerns with a current ratio of 0.18x.
Profusa remains essentially pre-revenue while posting very large operating and net losses, resulting in extreme negative margins. Liquidity is critically tight (current ratio 0.18, cash $3.01M vs. -$11.12M operating cash flow), and equity is deeply negative, signaling acute solvency and going‑concern risk without immediate external financing. While long‑term debt is low, the scale of losses and near-term cash needs overwhelm.
Profusa, Inc. Key Strengths (NVACW)
- Operating in high-growth medical devices sector (surgical instruments)
- 9 Form 4 insider filings suggest ongoing corporate activity
- Retained $3.0M in cash and equivalents as of latest period
- Low long-term debt ($713K) limits fixed interest burden
- Nasdaq listing may facilitate access to external capital
- Cash on hand ($3.01M), albeit limited, provides short runway
NVACW Stock Risks: Profusa, Inc. Investment Risks
- Negative stockholders' equity of -$34.0M indicates balance sheet insolvency
- Critical liquidity crisis with current ratio of 0.18x and liabilities exceeding assets by $34.0M
- Unsustainable cash burn of -$11.1M annually with minimal revenue generation ($100K) cannot support operations
- Operating margin of -24,136% demonstrates complete operational failure to generate revenue relative to expenses
- Severe liquidity shortfall and negative equity indicate solvency risk
- Sustained heavy losses and FCF burn with minimal revenue traction
- High dependence on external financing and likely dilution to continue operations
Key Metrics to Watch
- Path to revenue generation and product commercialization timeline
- Monthly cash burn rate and runway until capital depletion
- Balance sheet restructuring or capital raise announcements to address negative equity
- Operating cash flow (quarterly burn)
- Cash & equivalents (runway)
Profusa, Inc. (NVACW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
NVACW Profit Margin, ROE & Profitability Analysis
NVACW vs Healthcare Sector: How Profusa, Inc. Compares
How Profusa, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Profusa, Inc. Stock Overvalued? NVACW Valuation Analysis 2026
Based on fundamental analysis, Profusa, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Profusa, Inc. Balance Sheet: NVACW Debt, Cash & Liquidity
NVACW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Profusa, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-357.14 indicates the company is currently unprofitable.
NVACW Revenue Growth, EPS Growth & YoY Performance
NVACW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $75.0K | -$2.1M | $-0.70 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Profusa, Inc. Dividends, Buybacks & Capital Allocation
NVACW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Profusa, Inc. (CIK: 0001859807)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NVACW
What is the AI rating for NVACW?
Profusa, Inc. (NVACW) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NVACW's key strengths?
Claude: Operating in high-growth medical devices sector (surgical instruments). 9 Form 4 insider filings suggest ongoing corporate activity. ChatGPT: Low long-term debt ($713K) limits fixed interest burden. Nasdaq listing may facilitate access to external capital.
What are the risks of investing in NVACW?
Claude: Negative stockholders' equity of -$34.0M indicates balance sheet insolvency. Critical liquidity crisis with current ratio of 0.18x and liabilities exceeding assets by $34.0M. ChatGPT: Severe liquidity shortfall and negative equity indicate solvency risk. Sustained heavy losses and FCF burn with minimal revenue traction.
What is NVACW's revenue and growth?
Profusa, Inc. reported revenue of $100.0K.
Does NVACW pay dividends?
Profusa, Inc. does not currently pay dividends.
Where can I find NVACW SEC filings?
Official SEC filings for Profusa, Inc. (CIK: 0001859807) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NVACW's EPS?
Profusa, Inc. has a diluted EPS of $-2.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NVACW's fundamental grade?
Based on our AI fundamental analysis in June 2026, Profusa, Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NVACW stock overvalued or undervalued?
Valuation metrics for NVACW: ROE of N/A (sector avg: 15%), net margin of -27,256.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NVACW's AI grade for 2026?
Our dual AI analysis gives Profusa, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NVACW's free cash flow?
Profusa, Inc.'s operating cash flow is $-11.1M, with capital expenditures of N/A. FCF margin is -11,119.0%.
How does NVACW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -27,256.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.18 (avg: 2).